Gall Matthew's most recent trade in Kalaris Therapeutics Inc. was a trade of 95,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics Inc | Matthew Gall | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Expand Energy | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 110.89 per share. | 05 Jun 2025 | 1,804 | 16,917 (0%) | 0% | 110.9 | 200,046 | Common Stock |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 24,000 | 89,429 | - | 0 | Common Stock | |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 7.73 per share. | 19 Nov 2024 | 5,000 | 65,429 | - | 7.7 | 38,635 | Common Stock |
| Expand Energy | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 89.55 per share. | 06 Jun 2024 | 2,234 | 15,113 (0%) | 0% | 89.6 | 200,055 | Common Stock |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 163,200 | 163,200 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | Gall Matthew | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 41,000 | 60,429 | - | 0 | Common Stock | |
| Expand Energy | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 79.17 per share. | 08 Jun 2023 | 2,842 | 12,879 (0%) | 0% | 79.2 | 225,001 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 1,046 | 117,222 (0%) | 0% | 0 | Common Stock | |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Expand Energy | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 92.10 per share. | 09 Jun 2022 | 2,443 | 10,037 (0%) | 0% | 92.1 | 225,000 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 891 | 116,176 (0%) | 0% | 0 | Common Stock | |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Sale of securities on an exchange or to another person at price $ 240.11 per share. | 01 Mar 2022 | 21,599 | 118,686 (0%) | 0% | 240.1 | 5,186,157 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Sale of securities on an exchange or to another person at price $ 241.02 per share. | 01 Mar 2022 | 3,401 | 115,285 (0%) | 0% | 241.0 | 819,716 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Sale of securities on an exchange or to another person at price $ 229.64 per share. | 24 Feb 2022 | 11,833 | 145,929 (0%) | 0% | 229.6 | 2,717,342 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Sale of securities on an exchange or to another person at price $ 230.16 per share. | 24 Feb 2022 | 5,644 | 140,285 (0%) | 0% | 230.2 | 1,299,040 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Sale of securities on an exchange or to another person at price $ 230.17 per share. | 24 Feb 2022 | 2,523 | 157,762 (0%) | 0% | 230.2 | 580,729 | Common Stock |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.45 per share. | 27 Dec 2021 | 5,000 | 14,429 | - | 46.5 | 232,250 | Common Stock |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2021 | 14,429 | 42,388 | - | - | Stock Option (right to buy) | |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.16 per share. | 11 Oct 2021 | 14,429 | 19,429 | - | 6.2 | 88,883 | Common Stock |
| ITeos Therapeutics Inc | Matthew Gall | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 26.09 per share. | 16 Jun 2021 | 5,000 | 5,000 | - | 26.1 | 130,447 | Common Stock |
| Pioneer Natural Resources Co | Matthew M. Gallagher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 1,456 | 160,285 (0%) | 0% | 0 | Common Stock |